Reaktion #628209

ord-bb18f512ba4f4cff99d388057c2a592b

Reaktionsgleichung

NC(=O)CC[C@H](N)C(=O)O
L-glutamine
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[K+]
penicillin
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
streptomycin
Cc1cccc(NC(c2ccc([N+](=O)[O-])cc2)c2ccc3cccc(O)c3n2)n1
(6-methylpyridin-2-ylamino (4-nitrophenyl)methyl)quinolin-8-ol
→
Cc1cccc(NC(c2ccc([N+](=O)[O-])cc2)c2ccc3cccnc3c2O)n1
7-((6-methylpyridin-2-ylamino) (4-nitrophenyl)methyl)quinolin-8-ol

Edukte

—
compound
NC(=O)CC[C@H](N)C(=O)O
L-glutamine
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[K+]
penicillin
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
streptomycin
—
compound
Cc1cccc(NC(c2ccc([N+](=O)[O-])cc2)c2ccc3cccc(O)c3n2)n1
(6-methylpyridin-2-ylamino (4-nitrophenyl)methyl)quinolin-8-ol

Reagenzien

Keine

Lösungsmittel

CS(C)=O
DMSO
CS(C)=O
DMSO

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    workup.ADDITIONwas added before electrophoresis
  2. 2
    workup.ADDITIONwas added
  3. 3
    workup.ADDITIONwas added to it at the final
  4. 4
    Einengenconcentration

Vorschrift

H9c2 rat embryonic myocardial cells (from ATCC, Rockville, Md., USA) were grown in Dulbecco's modified eagle's medium containing 10% cattle serum, 4 mM L-glutamine (Sigma-Aldrich, Hungary), 100 IU/ml penicillin and 100 ug/ml streptomycin. To the H9c2 supernatant sample, 30 uM of the compound according to Example 1 (7-((6-methylpyridin-2-ylamino (4-nitrophenyl)methyl)quinolin-8-ol from a stock solution containing 30 mM of DMSO (1000-fold dilution) was added before electrophoresis. To the control, DMSO not containing the compound according to Example 1 was added. After electrophoresis, the gel was cut in two halves following renaturation one half was incubated in such a way that 30 uM of the compound, according to Example 1 was added to it at the final concentration, while the second half (control) was incubated without it. The compound according to Example 1 completely inhibited the 72 kDa gelatinase (MMP-2) if the substance was present during incubation. It inhibited the 92 kDa gelatinase (MMP-9) as well, hut to a less extent than the 72 kDa gelatinase,

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08871937B2uspto-grants-2014_10